News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,248 Results
Type
Article (39743)
Company Profile (248)
Press Release (660257)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204195)
Career Advice (2008)
Deals (35424)
Drug Delivery (95)
Drug Development (81054)
Employer Resources (172)
FDA (16189)
Job Trends (14864)
News (345239)
Policy (32547)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (49447)
ALS (96)
Alzheimer's disease (1385)
Antibody-drug conjugate (ADC) (133)
Approvals (16187)
Artificial intelligence (265)
Autoimmune disease (22)
Automation (17)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (176)
Bladder cancer (80)
Brain cancer (27)
Breast cancer (293)
Cancer (2328)
Cardiovascular disease (180)
Career advice (1677)
Career pathing (30)
CAR-T (159)
Cell therapy (443)
Cervical cancer (20)
Clinical research (66106)
Collaboration (859)
Company closure (2)
Compensation (572)
Complete response letters (19)
COVID-19 (2590)
CRISPR (41)
C-suite (252)
Cystic fibrosis (102)
Data (2353)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (275)
Diagnostics (6384)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (121)
Drug pricing (105)
Drug shortages (25)
Duchenne muscular dystrophy (98)
Earnings (87152)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112704)
Executive appointments (746)
FDA (17579)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (777)
Gene editing (109)
Generative AI (20)
Gene therapy (318)
GLP-1 (720)
Government (4432)
Grass and pollen (4)
Guidances (169)
Healthcare (18820)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (125)
Indications (29)
Infectious disease (2735)
Inflammatory bowel disease (143)
Inflation Reduction Act (9)
Influenza (52)
Intellectual property (99)
Interviews (312)
IPO (16530)
IRA (40)
Job creations (3633)
Job search strategy (1422)
Kidney cancer (10)
Labor market (43)
Layoffs (475)
Leadership (17)
Legal (7910)
Liver cancer (76)
Lung cancer (326)
Lymphoma (159)
Machine learning (9)
Management (58)
Manufacturing (329)
MASH (78)
Medical device (13390)
Medtech (13395)
Mergers & acquisitions (19476)
Metabolic disorders (710)
Multiple sclerosis (83)
NASH (16)
Neurodegenerative disease (95)
Neuropsychiatric disorders (27)
Neuroscience (1949)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (40)
Obesity (372)
Opinion (205)
Ovarian cancer (81)
Pain (91)
Pancreatic cancer (88)
Parkinson's disease (154)
Partnered (22)
Patents (245)
Patient recruitment (116)
Peanut (46)
People (57360)
Pharmaceutical (63)
Pharmacy benefit managers (20)
Phase I (20601)
Phase II (29119)
Phase III (21676)
Pipeline (1432)
Policy (147)
Postmarket research (2563)
Preclinical (8764)
Press Release (64)
Prostate cancer (108)
Psychedelics (30)
Radiopharmaceuticals (247)
Rare diseases (386)
Real estate (5907)
Recruiting (65)
Regulatory (22332)
Reports (48)
Research institute (2321)
Resumes & cover letters (349)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (72)
Series A (133)
Series B (91)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3580)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (51)
The Weekly (30)
Vaccines (699)
Venture capitalists (42)
Weight loss (237)
Women's health (36)
Worklife (16)
Date
Today (201)
Last 7 days (935)
Last 30 days (3353)
Last 365 days (32485)
2025 (12124)
2024 (35219)
2023 (40078)
2022 (51174)
2021 (55711)
2020 (54085)
2019 (46539)
2018 (35022)
2017 (32110)
2016 (31481)
2015 (37553)
2014 (31319)
2013 (26346)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (37886)
Australia (6196)
California (6482)
Canada (2077)
China (539)
Colorado (275)
Connecticut (282)
Delaware (159)
Europe (81451)
Florida (963)
Georgia (217)
Idaho (57)
Illinois (549)
India (25)
Indiana (323)
Iowa (11)
Japan (173)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (927)
Massachusetts (4812)
Michigan (226)
Minnesota (406)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (63)
New Jersey (1803)
New Mexico (28)
New York (1821)
North Carolina (993)
North Dakota (8)
Northern California (2871)
Ohio (210)
Oklahoma (14)
Oregon (34)
Pennsylvania (1438)
Puerto Rico (13)
Rhode Island (33)
South America (1097)
South Carolina (26)
South Dakota (1)
Southern California (2433)
Tennessee (107)
Texas (962)
United States (24221)
Utah (188)
Virginia (153)
Washington D.C. (64)
Washington State (569)
West Virginia (3)
Wisconsin (58)
700,248 Results for "abcam inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Abcam appoints Markus Lusser as new President
Abcam today announced the appointment of Markus Lusser as President.
March 18, 2024
·
2 min read
Deals
Danaher Completes Acquisition of Abcam
Danaher Corporation (NYSE:DHR) (“Danaher”) announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) (“Abcam”).
December 6, 2023
·
1 min read
Deals
Shareholders of Abcam Approve Proposed Acquisition by Danaher
Abcam plc, a global leader in the supply of life science research tools, which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation, announced that its shareholders have approved the proposal for Danaher to acquire all of the outstanding shares of Abcam for $24.00 per share in cash.
November 6, 2023
·
11 min read
Deals
Abcam Files and Mails Scheme Circular Seeking Approval of Acquisition of Abcam by Danaher for $24.00 per Share
CAMBRIDGE, England & WALTHAM, Mass.--( BUSINESS WIRE )-- Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today filed and mailed a scheme circular (the ‘Scheme Circular‘) in connection with the acquisition of Abcam by Danaher Corporation (NYSE: DHR) (‘Danaher’), announced on August 28, 2023 (the ‘Transaction’). Under the terms of the Transaction Agreement, Danaher will acquire all of the outstanding shares of Abc
October 5, 2023
·
15 min read
Deals
Danaher to acquire Abcam for $24.00 per Share
Abcam plc, a global leader in the supply of life science research tools, announced that it has entered into a definitive agreement pursuant to which Danaher Corporation will acquire all of the outstanding shares of Abcam for $24.00 per share in cash.
August 28, 2023
·
11 min read
Genetown
Abcam plc: All Resolutions Withdrawn at Abcam’s EGM
Abcam plc, a global leader in the supply of life science research tools, held an Extraordinary General Meeting of its shareholders that was convened following a requisition notice from Dr. Jonathan Milner dated May 30, 2023.
July 12, 2023
·
2 min read
Deals
Leading Proxy Advisor, ISS, Recommends Shareholders Vote “FOR” Danaher Corporation’s Proposed Acquisition of Abcam
Abcam plc, a global leader in the supply of life science research tools, announced that leading independent proxy advisor Institutional Shareholder Services, recommended that Abcam shareholders vote “FOR” Danaher Corporation’s proposed acquisition of Abcam ahead of its shareholder meetings on November 6, 2023.
October 17, 2023
·
14 min read
Deals
Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales
Abcam plc, a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation for $24.00 per share in cash, to be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006.
December 4, 2023
·
10 min read
Business
Abcam plc: FY2024 Guidance
Abcam plc, a global leader in the supply of life science research tools, provides the following updates.
June 26, 2023
·
9 min read
Genetown
Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023
Abcam plc which entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation for $24.00 per share in cash, announced that all Identified Clearances required in connection with the Transaction have been obtained from the relevant Governmental Authorities.
November 17, 2023
·
11 min read
1 of 70,025
Next